Summary
Although the novel cytidin analogue gemcitabine has shown superior anti-tumour activity than 5-fluorouracil in advanced pancreatic cancer, further improvements of therapeutic results are warranted. This goal might be achieved by combining gemcitabine with other active drugs. This trial evaluated the efficacy and tolerance of such a combination regimen with epirubicin and granulocyte colony-stimulating factor (G-CSF) in patients with metastatic disease. Seventy patients with metastatic pancreatic adenocarcinoma were enrolled in this multicentre trial. Patients received 4-weekly courses of a combination regimen consisting of epirubicin 60 mg m–2 given as intravenous bolus injection on day 1, gemcitabine 1000 mg m–2 infused over 30 min on days 1, 8 and 15, and G-CSF administered at 5 μg kg–1 day–1 subcutaneously from days 2–6 during each cycle. The efficacy of treatment was assessed by conventional measures, i.e. objective response, progression-free and overall survival, as well as by analysis of clinical benefit response (defined as ≥ 50% reduction in pain intensity, ≥ 50% reduction in daily analgesic consumption, and/or ≥ 20-point improvement in Karnofsky performance status that was sustained for ≥ 4 consecutive weeks). Of 66 patients evaluable for objective response, one achieved complete and 13 partial remissions, for an overall response rate of 21% (95% confidence interval (CI), 12–33%); 27 additional patients (41%) had stable and 25 (38%) increasing disease. The median time to progression was 3.8 months. Median survival was 7.8 months, and the probability of surviving beyond 12 months was 21.2%. Out of 60 patients with tumour-related symptoms, who were considered evaluable for clinical benefit response, 26 (43%) experienced significant palliation. The median time to achieve a clinical benefit response was 7 weeks, and its median duration was 22 weeks. Chemotherapy was well-tolerated with leukopenia/granulocytopenia representing the most common and dose-limiting side-effect. Gastrointestinal and other subjective toxicities were infrequent and generally rated minor. We conclude that the combination of gemcitabine, epirubicin and G-CSF seems to be an effective palliative treatment with only moderate toxic effects in patients with metastatic pancreatic adenocarcinoma. Our results in terms of objective and clinical benefit response, as well as survival seem to suggest an advantage over gemcitabine-monotherapy, though this remains to be confirmed in a randomized trial.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Anderson, J. R., Bernstein, L. & Pike, M. C. (1982). Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis. Biometrics 38: 407–416.
Andre, T., Lotz, J. P., Bouleuc, C., Azzouzi, K., Houry, S., Hannoun, L., See, J., Esteso, A., Avenin, D. & Izrael, V. (1996). Phase II trial of 5-fluorouracil, leucovorin and cisplatin for the treatment of advanced pancreatic adenocarcinoma. Ann Oncol 7: 173–178.
Burris, III H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, A., Stephens, C. D. & Von Hoff, D. D. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomised trial. J Clin Oncol 15: 2403–2413.
Cascinu, S., Silva, R. R., Barni, S., Labianca, R., Frontini, L., Pancera, G., Zaniboni, A., Ferretti, B., Giordani, P., Pessi, M. A., Fusco, V., Luporini, G., Catalano, G. & Cellerino, R. (1998). Gemcitabine (GEM) and 5-fluorouracil (5FU) in advanced pancreatic cancer: a GISCAD phase II study. Proc Am Soc Clin Oncol 17: 264a (abstract)
Casper, E. S., Green, M. R., Kelsen, D. P., Heelan, R. T., Brown, T. D., Flombaum, C. D., Trochanowski, B. & Tarassoff, P. G. (1994). Phase II trial of gemcitabine (2′2′-difluorodeoxy-cytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29–34.
Cortes-Funes, H., Castellano, D., Paz-Ares, L., Gravalos, C., Alonso, S., Hitt, R. & Hidalgo, M. (1998). A phase I–II study of gemcitabine (GEM) plus continuous infusion (CI) 5-fluorouracil (5-FU) in patients with advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 17: 265a (abstract)
Garcia-Conde, J., Lluch, A., Perez-Manga, G., Palomero, I., Alba, E., Rueda, A., Moreno-Noguiera, Calvo, E., Tarazona, Y. & Lopez-Martin, E. (1997). Gemcitabine + doxorubicin in advanced breast cancer: final results from an early phase II study. Proc Am Soc Clin Oncol 16: 147 (abstract)
Gehan, E. A. (1961). The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chron Dis 13: 346–353.
Heinemann, V., Wilke, H., Possinger, K., Mergenthaler, K., Clemens, M., König, H. J., Illiger, H. J., Lackhoff, A., Blatter, J., Schallhorn, A. & Fink, U. (1997). Activity and tolerability of gemcitabine plus cisplatin in advanced metastatic pancreatic carcinoma. Eur J Cancer 33: 274 (abstract)
Hertel, L. W., Boder, G. B., Kroin, J. S., Rinzel, S. M., Poore, G. A., Todd, G. C. & Grindey, G. B. (1990). Evaluation of the antitumor activity of gemcitabine (2′2′-difluoro-2′-deoxycytidine). Cancer Res 50: 4417–4422.
Kaplan, E. L. & Meier, P. (1958). Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 458–481.
Kornek, G., Raderer, M., Schenk, T., Pidlich, J., Schulz, F., Globits, S., Tetzner, C. & Scheithauer, W. (1995). Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma. Cancer 76: 1356–1362.
Lüftner, D., Grunewald, R., Flath, B., Akrivakis, C., Mergenthaler, H. G., Blatter, J. & Possinger, K. (1996). Gemcitabine with dose escalated epirubicin in advanced breast cancer: results of a phase I study. Ann Oncol 7 17: (abstract)
Miller, A. B., Hoogstraten, B. & Staquet, M. (1981). Reporting results of cancer treatment. Cancer 147: 207–214.
Parker, S. I., Tong, T. & Bolden, S. (1996). Cancer statistics 1996. CA Cancer Clin J 65: 5–27.
Ribas, A., Albanell, J., Bellmunt, J., Sole-Calvo, L. S., Bermejo, B., Gallardo, E., Vidal, R., Vera, R., Eres, N., Carulla, J. & Baselga, J. (1996). Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. J Clin Oncol 14: 1573–1580.
Rothenberg, M. L., Moore, M. J., Cripps, M. C., Andersen, J. S., Portenoy, R. K., Burris, HAIII, Green, M. R., Tarassoff, P. G., Brown, T. D., Casper, J. S., Storniolo, A. M. & Von Hoff, D. D. (1996). A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann Oncol 7: 347–353.
Schnall, S. F. & Macdonald, J. S. (1996). Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23: 220–228.
Warshaw, A. L. & Fernandez-del Castillo, C. (1992). Pancreatic carcinoma. N Engl J Med 326: 455–465.
Wils, J., Bleiberg, J., Blijham, G., Dalesio, O., Duez, N., Lacave, A. & Splinter, T. (1985). Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 21: 191–194.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Scheithauer, W., Kornek, G., Raderer, M. et al. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Br J Cancer 80, 1797–1802 (1999). https://doi.org/10.1038/sj.bjc.6690600
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690600
Keywords
This article is cited by
-
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)
BMC Cancer (2008)
-
Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas
Journal of Gastroenterology (2007)
-
A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma
British Journal of Cancer (2006)
-
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma
Cancer Chemotherapy and Pharmacology (2006)
-
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid
British Journal of Cancer (2003)